SCHEDULE 13D/A: Major Shareholder Richard Griffiths Boosts Stake in Silence Therapeutics to 20.7%

Sentiment:

Ownership Disclosure 31 March 2025 2:50 PM

📋All filings for Silence Therapeutics PLC

Richard Ian Griffiths, through various controlled entities, has increased his beneficial ownership in Silence Therapeutics Plc to 20.7% of outstanding ordinary shares following recent open market purchases totaling $3.0 million.

Summary

Richard Ian Griffiths, along with entities he controls, has filed Amendment No. 6 to Schedule 13D, updating his beneficial ownership in Silence Therapeutics Plc.
The amendment reflects open market purchases of the Issuer's American Depositary Shares (ADSs) and dilution due to an increase in the Issuer's share capital.
Mr. Griffiths' aggregate beneficial ownership now stands at 29,283,897 ordinary shares, representing 20.7% of the Issuer's outstanding ordinary shares, based on 141,664,074 shares outstanding as of December 11, 2024.
Ora Capital Limited, an entity controlled by Mr. Griffiths, beneficially owns 19,221,525 ordinary shares, representing 13.6% of the class, based on 141,664,487 shares outstanding as of December 11, 2024.
Between December 17, 2024, and March 31, 2025, Mr. Griffiths purchased an aggregate of 672,632 ADSs in open market transactions for a total price of $3.0 million.
These purchases were funded by cash from companies or personal funds of Mr. Griffiths.

Sentiment

Score: 7

Explanation: The filing indicates a significant increase in beneficial ownership by a key shareholder, Richard Ian Griffiths, through substantial open market purchases. This demonstrates strong confidence in the company's prospects from a well-informed insider, which is generally viewed positively by the market.

Positives

The increased stake by a significant shareholder, Richard Ian Griffiths, demonstrates continued confidence in Silence Therapeutics Plc.
The aggregate purchase of 672,632 ADSs for $3.0 million indicates a substantial investment by the reporting person.

Future Outlook

The document does not provide specific forward-looking statements or guidance regarding the Issuer's future operations or financial performance, as it is primarily an ownership disclosure.

Management Comments

"Mr. Griffiths is a director and the controlling shareholder of each of Ora Capital Limited, Ora Ventures Limited, Blake Holdings Limited, Sarossa Plc and Cream Capital Limited and a controlling shareholder of Pinkey's Limited and possesses the power to direct the voting and disposition of these shares."
"This Amendment does not change the information previously reported under this item."

Industry Context

This filing is an ownership disclosure and does not provide specific details on broader industry trends or competitive landscape for Silence Therapeutics Plc. However, increased insider ownership can sometimes signal confidence in the company's future within its sector, which is typically biotechnology or pharmaceuticals given the 'Therapeutics' in the name.

Comparison to Industry Standards

The document does not provide information for comparison to global benchmarks, specific comparable companies, projects, or results, as it is an ownership disclosure filing rather than a financial performance report.

Related Party Transactions

Richard Ian Griffiths is the controlling shareholder and director of Ora Capital Limited, Ora Ventures Limited, Blake Holdings Limited, Sarossa Plc, and Cream Capital Limited, and a controlling shareholder of Pinkey's Limited.
His beneficial ownership includes shares held by these entities, indicating transactions and holdings are managed through related parties under his control.

Stakeholder Impact

Shareholders: The increased stake by a significant investor may be perceived positively, signaling confidence and potentially stabilizing the share price.
Management: The continued investment by a controlling shareholder could reinforce alignment between management and major ownership interests.

Key Dates

Date	Description
06/15/2022	Original Schedule 13D filed with the SEC.
07/20/2022	Amendment to Schedule 13D filed.
10/20/2022	Amendment to Schedule 13D filed.
08/14/2023	Amendment to Schedule 13D filed.
03/27/2024	Amendment to Schedule 13D filed.
12/11/2024	Issuer's Statement of Capital filed with Companies House, disclosing 141,664,074 and 141,664,487 outstanding ordinary shares.
12/17/2024	Start date of the period for open market ADS transactions by Richard Ian Griffiths.
12/18/2024	Amendment to Schedule 13D filed.
02/13/2025	Richard Griffiths purchased 60,000 ADSs at $4.17 and 92,774 ADSs at $4.29.
02/18/2025	Richard Griffiths purchased 60,000 ADSs at $4.85.
03/05/2025	Richard Griffiths purchased 22,632 ADSs at $4.50.
03/27/2025	Richard Griffiths purchased 50,000 ADSs at $3.32.
03/28/2025	Richard Griffiths purchased 50,000 ADSs at $3.58.
03/31/2025	Date of event requiring filing of this statement; Richard Griffiths purchased 100,000 ADSs at $3.46; Date of signing of the Schedule 13D Amendment No. 6.

Recommendation

hold

Keywords

Silence Therapeutics Plc, Richard Ian Griffiths, Schedule 13D, Beneficial Ownership, Ordinary Shares, American Depositary Shares, Shareholder Stake, Open Market Purchases, Investment, Biotechnology, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.